Targeted Therapies In Renal Cell Carcinoma

Co-Host: Jay Raman, MD, FACS At the conclusion of these activities, participants will be able to: 1. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC. 2. Facilitate discussions with patients and caregivers regarding RCC treatment options. CME Available: auau.auanet.org/node/26091 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma